Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: November 17, 2009
Last updated: November 2, 2016
Last verified: November 2016
The goal of this clinical research study is to find the highest tolerable dose of the combination of dasatinib, bevacizumab, and paclitaxel with or without Methylnaltrexone that can be given to patients with advanced cancer. The safety of this drug combination will also be studied.

Condition Intervention Phase
Advanced Cancer
Drug: Dasatinib
Drug: Bevacizumab
Drug: Paclitaxel
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Trial of Dasatinib (Src Inhibitor), Bevacizumab (Anti-VEGF Monoclonal Antibody) and Metronomic Paclitaxel + or - Methylnaltrexone in Patients With Advanced Malignancies

Resource links provided by NLM:

Further study details as provided by M.D. Anderson Cancer Center:

Primary Outcome Measures:
  • Maximum Tolerated Dose (MTD) of Dasatinib, Bevacizumab and Paclitaxel + or - Methylnaltrexone in Advanced or Metastatic Cancer That is Refractory to Standard Treatment [ Time Frame: Continuous assessment during each dose level/28-day cycle ]
    MTD defined as the highest dose below any dose that has one third or more patients with dose limiting toxicities (DLT).

Secondary Outcome Measures:
  • Antitumor Efficacy of the Combination of Dasatinib, Bevacizumab and Paclitaxel + or - Methylnaltrexone in Advanced or Metastatic Cancer That is Refractory to Standard Treatment [ Time Frame: 28 days after the last dose of study drugs ]
    Participants with lymphoma measured per the WHO criteria, and all others evaluated using RECIST criteria version 1.1.

Estimated Enrollment: 218
Study Start Date: November 2009
Estimated Primary Completion Date: November 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dasatinib, Bevacizumab + Paclitaxel

Dose Escalation Starting Dose Levels: 50 mg Dasatinib daily by mouth (PO), 5 mg/kg Bevacizumab IV on Day 1 and 15; Paclitaxel 40 mg/m2 IV on Day 1, 8 and 15

Dose Expansion Starting Dose Levels: Maximum tolerated dose from Dose Escalation.

Drug: Dasatinib
Starting dose of 50 mg daily PO for 28 day cycle
Other Names:
  • BMS-354825
  • Sprycel
Drug: Bevacizumab
Starting dose 5 mg/kg IV Day 1 and 15
Other Names:
  • Avastin
  • Anti-VEGF monoclonal antibody
  • rhuMAb-VEGF
Drug: Paclitaxel
Starting dose 40 mg/m2 IV Day 1, 8 and 15
Other Name: Taxol

  Show Detailed Description


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients with advanced or metastatic cancer that is refractory to standard therapy, relapsed after standard therapy, or who have no standard therapy available that improves survival by at least three months.
  2. Patients must be >/= 3 weeks beyond treatment with a cytotoxic chemotherapy regimen, or therapeutic radiation, or major surgery. Patients may have received palliative localized radiation immediately before or during treatment providing radiation is not delivered to the only site of disease being treated under this protocol. After targeted/biologic therapy a patient has to be off treatment for 5 half-lives or 3 weeks whatever is shorter.
  3. ECOG performance status </= 2.
  4. Patients must have normal organ and marrow function defined as: absolute neutrophil count >/= 1,000/mL; platelets >/=90,000/mL; creatinine </= 2 X ULN; total bilirubin </= 2.0; ALT(SGPT) </= 5 X ULN; Exception for patients with liver metastasis: total bilirubin </= 3 x ULN; ALT(SGPT) </= 8 X ULN.
  5. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days after the last dose.
  6. Patients must be able to understand and be willing to sign a written informed consent document.

Exclusion Criteria:

  1. Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, uncontrolled asthma, need for hemodialysis, need for ventilatory support.
  2. Patients with hemoptysis within 28 days prior to entering the study.
  3. Patients with clinically significant unexplained bleeding within 28 days prior to the first dose of study medication.
  4. Uncontrolled systemic vascular hypertension (systolic blood pressure > 140mmHg, diastolic blood pressure > 90mmHg on medication).
  5. Patients with clinically significant cardiovascular disease: history of CVA within 6 months; myocardial infarction or unstable angina within 6 months.
  6. Major surgery within 28 days prior to Day 1 of dosing Bevacizumab.
  7. Pregnant or lactating women.
  8. History of hypersensitivity to dasatinib or any component of the formulation.
  9. History of hypersensitivity to bevacizumab, murine products, or any component of the formulation.
  10. History of hypersensitivity to paclitaxel or any component of the formulation.
  11. Patients with pleural effusion which is considered clinically significant by the attending physician.
  12. Patients unwilling or unable to sign informed consent document.
  13. Social situations that would limit compliance with study requirements.
  14. Patients receiving opioids within 2 weeks before signing the consent and patients, who cannot be off opioids until initiating the study medication (for methylnaltrexone arm only).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01015222

United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
Principal Investigator: Filip Janku, MD,PHD M.D. Anderson Cancer Center
  More Information

Additional Information:
Responsible Party: M.D. Anderson Cancer Center Identifier: NCT01015222     History of Changes
Other Study ID Numbers: 2009-0521
NCI-2012-01274 ( Registry Identifier: NCI CTRP )
Study First Received: November 17, 2009
Last Updated: November 2, 2016

Keywords provided by M.D. Anderson Cancer Center:
Advanced Malignancies
Metastatic cancer

Additional relevant MeSH terms:
Albumin-Bound Paclitaxel
Antibodies, Monoclonal
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Protein Kinase Inhibitors
Enzyme Inhibitors processed this record on April 24, 2017